Food and Drug Administration (FDA) approval of the subcutaneous injection formulation of Opdivo for patients with solid tumors. Intravenous (IV): when a needle is inserted into a vein to administer ...

Coya Therapeutics (COYA) announced encouraging blood biomarker data from an investigator-initiated, 21-week, double-blind, placebo-controlled, ...

Coya Therapeutics' Phase 2 study shows monthly LD IL-2 improves cognitive scores and reduces inflammation in Alzheimer's patients, with no serious adverse events.

The U.S. Food and Drug Administration approved Eisai and Biogen’s application ... lecanemab will halve the number of infusion center visits. The FDA will decide on subcutaneous maintenance dosing of ...

Operator Good day, and welcome to the Vertex Pharmaceuticals fourth quarter 2024 earnings call. All participants will be in a ...

Reshma Kewalramani; President, Chief Executive Officer, Director; Vertex Pharmaceuticals Inc Stuart Arbuckle; Chief Operating Officer, Executive Vice President; Vertex Pharmaceuticals Inc Charles ...

Q4 2024 Earnings Call Transcript February 10, 2025 Vertex Pharmaceuticals Incorporated misses on earnings expectations. Reported EPS is $3.98 EPS, expectations were $4.02. Operator: Good day, and ...

When there is loculation of the fluid from extensive adhesions or when the contents are extremely viscid (for example, in pseudomyxoma peritonei), administration of the gold by this trocar method ...

The proximity of the nose to the brain also leads to a more rapid equilibration between the blood and the cerebrospinal fluid ... to IV administration, and are generally superior to subcutaneous ...

The Global Implantable Drug Delivery Devices Market was valued at USD 26.7 Bn in 2023. It is expected to reach USD 57.1 Bn by 2033, with a CAGR of 8.1% ...